Outcome of Adolescents and Young Adults with Acute Myeloid Leukemia: A Single-Center Experience
Downloads
Abstract
Introduction: Little is known about the outcomes of Adolescent and young adults (AYAs); aged 15-39 years with acute myeloid leukemia (AML) worldwide, so, we evaluated the clinical characteristics, response to therapy, and survival outcomes of these patients.
Patients and Methods: In this observational prospective cohort study, we investigated 64 AYA AML patients, divided by their age at diagnosis into two groups, (AYA 16-29 years) and (AYA 30-39 years); including 26 and 20 patients, respectively. Patient and disease characteristics, in addition to treatment and survival outcomes, were analyzed using statistical package for social science software version 24
Results: The median age of the whole group was 29 years, with male-to-female ratio 1.3. The most common FAB subtypes were M2 and M4, 30.4% (for each subtype). Normal karyotyping represented the most frequent cytogenetic risk group (65.2%). An intensive induction therapy was given to most patients (82.6%) and a significant difference was found between the 2 patient groups regarding karyotyping and intensive induction therapy, P-value <0.001 and 0.048, respectively.
The complete remission rate was (65.2%) and the relapse rate was 40.0% which was significantly higher in the (AYA 16-29 year) group, P<0.001.
The 3-Year leukemia-free survival (LFS) rate was 23.6% and was significantly better within the (AYA 30-39 years) group, p-value = 0.002. While there was no significant difference in overall survival rates.
Conclusion: AYA patients constitute a unique subset of patients with AML with an improved prognosis especially those aged from 30-39 years, who had better LFS and lower relapse rates.
Keywords: Adolescent and young adults (AYAs), acute myeloid leukemia (AML), survival, prognosis.
Keegan THM, Ries LAG, Barr RD, Geiger AM, Dahlke DV, Pollock BH, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;
Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, et al. Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer. 2016.
Bleyer A, Tai E, Siegel S. Role of clinical trials in survival progress of American adolescents and young adults with cancer—and lack thereof. Pediatr Blood Cancer. 2018;
Tricoli J V., Boardman LA, Patidar R, Sindiri S, Jang JS, Walsh WD, et al. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. Cancer. 2018;
Zebrack BJ, Block R, Hayes-Lattin B, Embry L, Aguilar C, Meeske KA, et al. Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients. Cancer. 2013;
Ofran Y, Rowe JM. Acute myeloid leukemia in adolescents and young adults: Challenging aspects. Acta Haematol. 2014;
Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2010.
Jaime-Pérez JC, Padilla-Medina JR, Fernández LT, Herrera-Garza JL, Gutiérrez-Aguirre CH, Tarín-Arzaga L, et al. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center. Clin Lymphoma, Myeloma Leuk. 2018;
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, et al. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma, Myeloma Leuk. 2013;
Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A Report from the Children’s Oncology Group. Cancer. 2013;
B. H, M. L, R. M, N. K, S. C, M. Q, et al. Outcome of acute myeloid leukemia in children and young adults treated with an uniform protocol in Casablanca, Morocco. Blood. 2016;
Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, De Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood. 2012.
Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children’s oncology group Trial AAML0531. J Clin Oncol. 2014;
Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O’Brien S, et al. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML). Clin Lymphoma, Myeloma Leuk. 2016;
Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. British Journal of Haematology. 2012.
Pulte D, Gondos A, Brenner H. Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol. 2010;
Nasir SS, Giri S, Nunnery S, Martin MG. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia. Clin Lymphoma, Myeloma Leuk. 2017;
Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;
